ANNOVIS BIO INC: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei ANNOVIS BIO INC listata cu simbolul US.ANVS ==Descriere companie== Annovis Bio, Inc. (www.annovisbio.com) is a clinical-stage drug platform company. The Company is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The Company's lead compound, ANVS401, is an orally administered drug being developed for chronic indications...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Annovis Bio, Inc. (www.annovisbio.com) is a clinical-stage drug platform company. The Company is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The Company's lead compound, ANVS401, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The Company's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as ANVS401, but it is given intravenously in cases of acute head and brain trauma. The Company is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia. | Annovis Bio, Inc. (www.annovisbio.com) is a clinical-stage drug platform company. The Company is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The Company's lead compound, ANVS401, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The Company's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as ANVS401, but it is given intravenously in cases of acute [[head]] and brain trauma. The Company is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||